# Pizarra — PT-pseudo_099651db404e (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_099651db404e
Task: 1

Encounter: Urology - outpatient on 17 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 5.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.14 ng/mL²
  - PSA velocity: 0.97 ng/mL/yr
  - Prior PSA: 5.2 ng/mL
  - Prostate volume: 44.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7418201 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 5.9 ng/mL. PI-RADS 5. PSAD 0.14. Prostate volume 44 mL. csPCa 0.74.

Vitals: weight 113 kg, height 186 cm, BMI 32.7, BP 117/68 mmHg, HR 68 bpm. Smoking: Ex-smoker (39 pack-yr, quit 2010).

Chief complaint: Persistent elevation of prostate-specific antigen alongside a previous negative biopsy necessitates specialist review.

History: Originally referred for a 3.9 ng/mL prostate-specific antigen reading in 2022, this 54-year-old retired farmer has completed a negative biopsy yet continues to report moderate lower urinary tract symptoms, currently registering 13 on the IPSS questionnaire. He resides alone and has never married, maintaining his daily routine through a brisk 20-minute walk, accompanied by a modest three units of alcohol per week. His medical background remains clear apart from a substantial 39 pack-year smoking history, which he ceased in 2010. A recent audiology visit for routine hearing screening and his annual influenza vaccination proceeded without incident. Traveling over an hour by train for clinic appointments, he approaches his ongoing urological follow-up with a practical, straightforward mindset.

Physical examination: DRE: The prostate presents as symmetrically smooth, maintaining normal dimensions and consistency without palpable nodules or asymmetry. General examination shows stable vital signs and a BMI of 32.7, with no abdominal masses or lymphadenopathy detected. The individual appears well-nourished and ambulates without assistance.

Patient info: retired farmer; Never married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Walking 20 min/day; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; GP practice nurse — flu vaccination.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.81 +/- 0.14   (95% CI 0.46-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.12  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.08  (few labelled cases resemble this one)
  - 7.3 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=1.0, psa=5.9, age=54.0, psad=0.14, dre_ord=0.0, vol=44.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5.0, PSA=5.9, PSA density=0.14, etc.) and failed to incorporate the context of the prior negative biopsy status, which is a critical factor in re-biopsy decisions. It did not weigh the patient's history of moderate LUTS (IPSS 13) or his significant smoking history (39 pack-yr), which are known risk factors that might influence the interpretation of the PI-RADS 5 score.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a high probability (0.81), but the guideline criterion suggests that a PI-RADS 4-5 lesion warrants re-biopsy, but the track record depends on specific retrieved data. The prior's high confidence interval might be misleading if the patient falls into a low-risk category based on PSA density or if the prior negative biopsy status should temper the decision.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_099651db404e", "radiology_report": "OLVG Amsterdam Radiology | 15 Jan 2025 | Study: mpMRI prostate\n\nClinical Indication:\nA 54-year-old gentleman presents with a climbing PSA curve (current 5.9 ng/mL) and a previous negative TRUS biopsy, prompting re-evaluation for occult malignancy.\n\nFINDINGS:\nThe prostate gland measures 44.0 mL and exhibits asymmetry. A discrete abnormality occupies the right peripheral zone at the mid-gland level, spanning roughly 12 x 9 mm. T2-weighted sequences show pronounced hypointensity within this focus. Diffusion-weighted imaging confirms restricted water movement with correspondingly low ADC values. Dynamic contrast-enhanced phases demonstrate early, focal enhancement compared to adjacent tissue. There is no extraprostatic extension, seminal vesicle invasion, or suspicious pelvic lymphadenopathy.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right mid peripheral zone. Prostate volume 44.0 mL yielding a PSA density of 0.14 ng/mL/mL. csPCa predicted probability 0.7418201."}
get_psa_trend
{"case_id": "PT-pseudo_099651db404e", "psa_trend": [{"date": "May 2022", "val": 3.4}, {"date": "Sep 2023", "val": 4.5}, {"date": "Jan 2025", "val": 5.9}]}
get_previous_notes
{"case_id": "PT-pseudo_099651db404e", "previous_notes": [{"date": "22 May 2024", "author": "Dr. T. Hendriks (GP)", "text": "Initial workup followed a PSA elevation to 3.9 ng/mL during May 2022. A subsequent climb to 5.2 ng/mL led to a systematic TRUS biopsy in late 2023, which returned entirely negative for malignancy. With PSA values remaining elevated and mild urinary complaints persisting, a urological re-evaluation was scheduled for further imaging and potential repeat sampling."}]}
get_lab_results
{"case_id": "PT-pseudo_099651db404e", "laboratory_results": [{"name": "PSA", "val": "5.9 ng/mL", "date": "23 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.39 ng/mL", "date": "23 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "24%", "date": "23 Dec 2024", "flag": ""}]}
NOT RETRIEVED
get_family_history
The family history of prostate cancer was not retrieved because it is not required for this decision based on the retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling:
- mpMRI report: PI-RADS 5 lesion in the right mid peripheral zone.
- PSA trend: Rising from 3.4 ng/mL (May 2022) to 5.9 ng/mL (Jan 2025).
- Previous notes: Prior negative biopsy, prompting re-evaluation for further imaging and potential repeat sampling.

AGAINST Sampling:
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly supports re-biopsy due to the PI-RADS 5 finding and the history of a prior negative biopsy, aligning with the EXPERT-PROTOCOL criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to recommend biopsy is driven by the PI-RADS 5 lesion identified on the mpMRI, which is decisive for re-biopsy according to the expert protocol. This finding is supported by the history of a prior negative biopsy, as documented in the previous notes. The rising PSA trend from 3.4 ng/mL to 5.9 ng/mL further supports the need for further investigation. The statistical prior also suggested biopsy, and the retrieved evidence converges on this recommendation.

Variables that carried weight: bx=decisive, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
